Dunad Therapeutics
Holly Whittemore has extensive experience in the biotechnology industry. Holly served as the Chief Operating Officer and Treasurer at Dunad Therapeutics starting from July 2023. Prior to that, they worked as a Consultant at Holly Whittemore, CPA from January 2012 to July 2023. Holly also held various roles at Nimbus Therapeutics, including Chief Accounting Officer from January 2009 to July 2023, and Chief Financial Officer from January 2019 to September 2021. Before joining Nimbus Therapeutics, they were the Head of Finance/Operations at Nimbus Discovery from March 2009 to December 2018.
Holly Whittemore attended the University of Virginia from 1987 to 1991, earning a Bachelor of Science degree in Commerce with a focus on Accounting.
This person is not in any offices
Dunad Therapeutics
1 followers
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.
Employees
11-50